Attached files
file | filename |
---|---|
EX-23.2 - EX-23.2 - Cascadian Therapeutics, Inc. | v58565exv23w2.htm |
EX-23.1 - EX-23.1 - Cascadian Therapeutics, Inc. | v58565exv23w1.htm |
EX-32.1 - EX-32.1 - Cascadian Therapeutics, Inc. | v58565exv32w1.htm |
EX-31.2 - EX-31.2 - Cascadian Therapeutics, Inc. | v58565exv31w2.htm |
EX-10.7.A - EX-10.7.A - Cascadian Therapeutics, Inc. | v58565exv10w7wa.htm |
EX-31.1 - EX-31.1 - Cascadian Therapeutics, Inc. | v58565exv31w1.htm |
EX-21.1 - EX-21.1 - Cascadian Therapeutics, Inc. | v58565exv21w1.htm |
EX-10.10.B - EX-10.10.B - Cascadian Therapeutics, Inc. | v58565exv10w10wb.htm |
EX-10.10.A - EX-10.10.A - Cascadian Therapeutics, Inc. | v58565exv10w10wa.htm |
10-K - FORM 10-K - Cascadian Therapeutics, Inc. | v58565e10vk.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)
I, Julia M. Eastland, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Oncothyreon Inc. on Form
10-K for the fiscal year ended December 31, 2010, fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual
Report on Form 10-K fairly presents, in all material respects, the financial condition and results
of operations of Oncothyreon Inc.
March 14, 2011 | /s/ Julia M. Eastland | |||
Julia M. Eastland, | ||||
Chief Financial Officer, Secretary and Vice President of Corporate Development (Principal Financial and Accounting Officer) |
||||
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act
of 2002 has been provided to Oncothyreon Inc. and will be retained by Oncothyreon Inc. and
furnished to the Securities and Exchange Commission or its staff upon request.
This certification accompanies this Report on Form 10-K pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed
filed by Oncothyreon Inc. for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act). Such certification will not be deemed to be incorporated by reference
into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the
extent that Oncothyreon Inc. specifically incorporates it by reference.